Rimm DL - Search Results

1

Validation of the IHC4 Breast Cancer Prognostic Algorithm Using Multiple Approaches on the Multinational TEAM Clinical Trial.

Bartlett JM, Christiansen J, Gustavson M, Rimm DL, Piper T, van de Velde CJ, Hasenburg A, Kieback DG, Putter H, Markopoulos CJ, Dirix LY, Seynaeve C, Rea DW. Bartlett JM, et al. Among authors: rimm dl. Arch Pathol Lab Med. 2016 Jan;140(1):66-74. doi: 10.5858/arpa.2014-0599-OA. Arch Pathol Lab Med. 2016. PMID: 26717057 Free article. Clinical Trial.

2

Expression of c-met is a strong independent prognostic factor in breast carcinoma.

Ghoussoub RA, Dillon DA, D'Aquila T, Rimm EB, Fearon ER, Rimm DL. Ghoussoub RA, et al. Among authors: rimm eb, rimm dl. Cancer. 1998 Apr 15;82(8):1513-20. doi: 10.1002/(sici)1097-0142(19980415)82:8<1513::aid-cncr13>3.0.co;2-7. Cancer. 1998. PMID: 9554529

3

Validation of tissue microarray technology in breast carcinoma.

Camp RL, Charette LA, Rimm DL. Camp RL, et al. Among authors: rimm dl. Lab Invest. 2000 Dec;80(12):1943-9. doi: 10.1038/labinvest.3780204. Lab Invest. 2000. PMID: 11140706 Free article.

4

Quantitative in situ analysis of beta-catenin expression in breast cancer shows decreased expression is associated with poor outcome.

Dolled-Filhart M, McCabe A, Giltnane J, Cregger M, Camp RL, Rimm DL. Dolled-Filhart M, et al. Among authors: rimm dl. Cancer Res. 2006 May 15;66(10):5487-94. doi: 10.1158/0008-5472.CAN-06-0100. Cancer Res. 2006. PMID: 16707478

5

Immunohistochemistry and quantitative analysis of protein expression.

Cregger M, Berger AJ, Rimm DL. Cregger M, et al. Among authors: rimm dl. Arch Pathol Lab Med. 2006 Jul;130(7):1026-30. doi: 10.5858/2006-130-1026-IAQAOP. Arch Pathol Lab Med. 2006. PMID: 16831029 Free article. Review.

6

Classification of breast cancer using genetic algorithms and tissue microarrays.

Dolled-Filhart M, Rydén L, Cregger M, Jirström K, Harigopal M, Camp RL, Rimm DL. Dolled-Filhart M, et al. Among authors: rimm dl. Clin Cancer Res. 2006 Nov 1;12(21):6459-68. doi: 10.1158/1078-0432.CCR-06-1383. Clin Cancer Res. 2006. PMID: 17085660

7

Antibody validation by quantitative analysis of protein expression using expression of Met in breast cancer as a model.

Pozner-Moulis S, Cregger M, Camp RL, Rimm DL. Pozner-Moulis S, et al. Among authors: rimm dl. Lab Invest. 2007 Mar;87(3):251-60. doi: 10.1038/labinvest.3700515. Epub 2007 Jan 29. Lab Invest. 2007. PMID: 17260003 Free article.

8

Quantitative analysis of estrogen receptor heterogeneity in breast cancer.

Chung GG, Zerkowski MP, Ghosh S, Camp RL, Rimm DL. Chung GG, et al. Among authors: rimm dl. Lab Invest. 2007 Jul;87(7):662-9. doi: 10.1038/labinvest.3700543. Epub 2007 Mar 5. Lab Invest. 2007. PMID: 17334408 Free article.

9

Quantitative analysis of breast cancer tissue microarrays shows high cox-2 expression is associated with poor outcome.

Zerkowski MP, Camp RL, Burtness BA, Rimm DL, Chung GG. Zerkowski MP, et al. Among authors: rimm dl. Cancer Invest. 2007 Feb;25(1):19-26. doi: 10.1080/07357900601128825. Cancer Invest. 2007. PMID: 17364553

10

Quantitative measurement of epidermal growth factor receptor is a negative predictive factor for tamoxifen response in hormone receptor positive premenopausal breast cancer.

Giltnane JM, Rydén L, Cregger M, Bendahl PO, Jirström K, Rimm DL. Giltnane JM, et al. Among authors: rimm dl. J Clin Oncol. 2007 Jul 20;25(21):3007-14. doi: 10.1200/JCO.2006.08.9938. J Clin Oncol. 2007. PMID: 17634479 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

517 results

Search Page

Filters